semaglutide fda approved for weight loss Drug Wegovy FDA-Approved Lowering Heart Disease Risk FDA Approves Game-Changing Weight Loss

Appetite & Craving Control Dual-hormone action helps reduce hunger and increase satiety naturally

Who should consider a cash-pay GLP-1 program Cash-pay GLP-1 programs typically suit individuals who: Have a BMI of 27 or higher with a weight-related comorbidity (high blood pressure, sleep apnea, prediabetes), or BMI of 30 or higher Have insurance that excludes weight loss medications, or have no prescription drug coverage Have tried lifestyle interventions without achieving sustained results Want the convenience and privacy of a fully telehealth-based experience Are comfortable with weekly self-injection (or are interested in oral/sublingual alternatives) GLP-1 medications are not appropriate for everyone

For others, a gentler approach with semaglutide or tirzepatide makes more sense

The rate of weight loss typically accelerates as users increase their dose, and many experience rapid weight loss in the first six months of treatment